Therapeutic antibodies have emerged as one of the promising approaches towards infectious disease sufferings. We are among the best organizations in the market and have been working on improving therapeutic antibodies. There is a wide range of services our company provides in terms of R&D process for the antibody drugs, such as preparing the antibody, screening, optimizing and then preparing it for preclinical research, we provide a one-stop solutions for the R&D process of infectious disease drugs.
Overview of Therapeutic Antibodies
Ever since the historic approval of the inaugural therapeutic monoclonal antibody (mAb) back in the distant year of 1986, the realm of therapeutic antibody drugs has embarked on an exhilarating journey of rapid development. Due to high specificity and low adverse reactions of mAbs, antibody drugs have been widely used in the treatment of infectious diseases. Therapeutic antibodies are capable of binding to specific targets, which allows them to modulate biological processes, neutralize harmful pathogens or amplify immune responses; hence, they are valuable tools in the fight against infectious diseases.
Fig. 1 Engineering therapeutic antibodies to combat infectious diseases. (Wagner E K, Maynard J A., 2018)
Market Size of Therapeutic Antibodies
The therapeutic antibodies segment has witnessed astounding expansion in the last few years, owing to the increasing need for suitable cures for infectious diseases. Research report estimates indicate that the size of the global monoclonal antibody therapeutic market is placed to be USD 252.6 billion in 2024 and USD 497.5 billion in 2029, growing at a CAGR of 14.5 percent during 2024 to 2029.
Fig. 2 Number of therapeutic antibodies against different targets and mAb targets currently in Phase 3 clinical trials. (Martineau P, et al., 2019)
Therapeutic Antibodies for Infectious Diseases
Thanks to the innovations in antibody development and screening technologies, a number of antibodies have been licensed for the treatment of various diseases.
| Therapeutic Antibodies |
Targets |
Mechanism |
Indications |
| Palivizumab |
Respiratory syncytial virus fusion (F) protein |
Prevent the fusion of the virus with the host cell |
Respiratory syncytial virus infection |
| Raxibacumab |
Bacillus anthracis protective antigen |
Block the binding of other components of the toxin to inhibit the toxin's harmful effects |
Anthrax infection |
| Bezlotoxumab |
Clostridium difficile toxin B |
Neutralize toxic effects of toxin B |
Clostridium difficile infection |
| Oritavancin |
Bacterial Cell Wall Precursor Lipid II |
Disrupt cell wall synthesis |
Skin infections caused by susceptible gram-positive bacteria |
Our Services
The area of infectious disease treatment has been transformed with the introduction of therapeutic antibodies that act against various pathogens. We offer one-stop solutions for the preparation, screening, optimization and characterization of antibodies due to our advanced technology platforms. Our company will focus on enhancing and developing highly creative therapeutic antibodies for the management and reduction of infectious diseases.
Antibody Preparation and Screening Platforms
- Hybridoma Technology
- Single B Cell Technology
- Phage display technology
- Yeast display technology
- Bacterial display technology
- Mammalian cell display technology
- Ribosome and mRNA display technology
- And More
Antibody Optimization and Characterization Platforms
- Antibody humanization
- Antibody affinity maturation
- Antibody fragmentation
- KD measurement
- Epitope mapping
- Purity and stability analysis
- Glycosylation analysis
- And More
Development Process of Therapeutic Antibodies
Antibody Characterization
Optional Antibody Types
- Monoclonal antibody (mAb)
- Polyclonal antibody (pAb)
- Bispecific antibody (BsAb)
- Antibody-drug conjugate (ADC)
- Single domain antibody (sdAb)
- And More
Applicable Disease Types
Our company is focused on advancing the boundaries of therapeutic antibody design. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Wagner E K, Maynard J A. Engineering therapeutic antibodies to combat infectious diseases[J]. Current opinion in chemical engineering, 2018, 19: 131-141.
- Martineau P, Watier H, Pèlegrin A, et al. Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France[C]//MAbs. Taylor & Francis, 2019, 11(5): 812-825.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
